I agree that this site is using cookies. You can find further informations here.
X
Nekkab, Narimane
160  results:
Search for persons X
?
1

Tafenoquine following G6PD screening versus primaquine for ..:

Price, David J. ; Nekkab, Narimane ; Monteiro, Wuelton M....
PLOS Medicine.  21 (2024)  1 - p. e1004255 , 2024
Link: https://doi.org/10.1371/..
 
?
2

Design and selection of drug properties to increase the pub..:

Braunack-Mayer, Lydia ; Malinga, Josephine ; Masserey, Thiery...
The Lancet Global Health.  12 (2024)  3 - p. e478-e490 , 2024
Link: https://doi.org/10.1016/..
 
?
3

One-way sensitivity analysis of the impact of changing the ..:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
doi:10.1371/journal.pmed.1004255.g002.  , 2024
Link: https://doi.org/10.1371/..
 
?
4

Map of incremental cost-effectiveness ratios (ICERs) in eac..:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
doi:10.1371/journal.pmed.1004255.g001.  , 2024
Link: https://doi.org/10.1371/..
 
?
5

One-way sensitivity analysis of the impact of changing the ..:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
doi:10.1371/journal.pmed.1004255.s003.  , 2024
Link: https://doi.org/10.1371/..
 
?
6

Cost-effectiveness planes showing the incremental costs and..:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
doi:10.1371/journal.pmed.1004255.s006.  , 2024
Link: https://doi.org/10.1371/..
 
?
7

Economic evaluation model code:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
doi:10.1371/journal.pmed.1004255.s002.  , 2024
Link: https://doi.org/10.1371/..
 
?
8

Cost-effectiveness acceptability curves for each tafenoquin..:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
doi:10.1371/journal.pmed.1004255.s007.  , 2024
Link: https://doi.org/10.1371/..
 
?
9

Cost-effectiveness planes showing the incremental costs and..:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
doi:10.1371/journal.pmed.1004255.s004.  , 2024
Link: https://doi.org/10.1371/..
 
?
10

Mean and 95% credible intervals from the probabilistic sens..:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
doi:10.1371/journal.pmed.1004255.s005.  , 2024
Link: https://doi.org/10.1371/..
 
?
11

Consolidated Health Economic Evaluation Reporting Standards..:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
doi:10.1371/journal.pmed.1004255.s001.  , 2024
Link: https://doi.org/10.1371/..
 
?
12

Cost-effectiveness acceptability curves overall in Brazil f..:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
doi:10.1371/journal.pmed.1004255.g003.  , 2024
Link: https://doi.org/10.1371/..
 
?
13

Parameters used in the economic evaluation, including diagn..:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
doi:10.1371/journal.pmed.1004255.t001.  , 2024
Link: https://doi.org/10.1371/..
 
?
14

Tafenoquine following G6PD screening versus primaquine for ..:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10775976/?tool=EBI.  , 2024
Link: https://doaj.org/article..
 
?
15

Total overall cases, costs, DALYs, and ICERs for Brazil fro..:

David J. Price ; Narimane Nekkab ; Wuelton M. Monteiro...
doi:10.1371/journal.pmed.1004255.t002.  , 2024
Link: https://doi.org/10.1371/..
 
1-15